Lonza, a global contract development and manufacturing organization (CDMO) for the pharmaceutical, biotech, and nutraceutical markets, announced today that it will invest...
Swiss contract development and manufacturing organization (CDMO) Lonza has announced a long-term extension of its collaboration with a key global biopharmaceutical...
Lonza has completed its acquisition of the Genentech large-scale biologics manufacturing site in Vacaville, California, USA, from Roche for $1.2 billion. The deal was...
Lonza inaugurated its new facility at the Colmar, France site. The new Innovaform Accelerator will serve as a Center of Excellence for developing and innovating capsule...
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine...
Driven by increased demand in biologic-based drugs, biologic drug substance manufacturing continues to be an active area of investment by contract development and...
Lonza recently announced that it has completed a planned expansion of the mid-scale microbial manufacturing facility at its Visp, Switzerland site. This multi-product...
